TRPM8 and neoplasm: In prostate cancer, D-3263 (an orally bioavailable small molecule that targets TRPM8) binds and activates TRPM8, induces Ca2+ to enter cells, causing the destruction of calcium ion homeostasis and cell death of tumor cells expressing TRPM8.